20241021-东吴证券-江苏吴中-600200.SH-2024年三季报点评_艾塑菲延续高增_医美业务成长可期_3页_471kb

Summary
This report provides an analysis and assessment of Jiangsu Wu Zhong (600200) based on its 2024 Q3 financial performance. The key points are:

1. Improved Performance: For the first nine months of 2024, Jiangsu Wu Zhong reported significant improvement, with revenue growth of 96% and net profit turning positive after a loss in the previous year. Q3 2024 specifically showed revenue growth of 95% and a return to profit due entirely from its medical aesthetics division.
2. Medical Aesthetics Growth: Driven by its flagship product, AestheFill (referred to as "Ai Shuo Fei"), the medical aesthetics division delivered remarkable results. Q3 revenue from this sector grew by 6560%, contributing significantly to overall positive profit. AestheFill is positioned as a premium filler, well-received due to its efficacy and safety, leading to strong sales.
3. Future Development: The company's medical aesthetics pipeline is extensive, with products like Hara Hyaluronic Acid, Lidocaine Lip膏, PDRN, and recombinant collagen under development or planned for development, aiming to further bolster future growth.
4. Trading Recommendation: The research maintains an "Buy" recommendation, supporting that positive outlook with EPS forecasts and valuations (P/E ratios) for 2024-2026. The target net profit figures and associated P/E multiples (63x, 30x, 19x) are projected.
5. Disclaimer: Standard disclaimer language accompanies the report.